信達生物(01801.HK)IBI323臨床研究完成中國首例給藥
信達生物(01801.HK)公布,旗下抗LAG-3/PD-L1雙特異性抗體產品IBI323,於一期臨床研究完成中國首例受試者給藥。
該項研究是於中國開展的開放、多中心一期劑量遞增和隊列擴展研究,主要目的為評估IBI323在標準治療失敗的晚期惡性腫瘤受試者中的安全性、耐受性和抗腫瘤活性。
信達生物制藥集團臨床開發高級副總裁周輝表示,初步研究結果顯示IBI323與兩種單克隆抗體藥物相比,在提高免疫效應之餘亦可提高給藥便捷性,預期開發LAG-3/PD-L1雙特異性抗體將為患者提供更新型、全面、有效且經濟的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.